Waiting times disparities for medication-assisted therapy among opioid use disorder treatment population in the United States

References

• Buresh M, Stern R, Rastegar D. Treatment of opioid use disorder in primary care. BMJ. 2021;373:n784. doi:10.1136/bmj.n784.
   PubMedGoogle Scholar
• Johnson K, Hills H, Ma J, Brown CH, McGovern M. Treatment for opioid use disorder in the Florida medicaid population: using a cascade of care model to evaluate quality. Am J Drug Alcohol Abuse. 2021;47(2):220–8. doi:10.1080/00952990.2020.1824236.
   PubMed Web of Science ®Google Scholar
• Kleber HD. Pharmacologic treatments for opioid dependence: detoxification and maintenance options. Dialog Clin Neurosci. 2007;9(4):455–70. doi:10.31887/DCNS.2007.9.2/hkleber.
   PubMedGoogle Scholar
• Campbell ANC, Barbosa-Leiker C, Hatch-Maillette M, Mennenga SE, Pavlicova M, Scodes J, Saraiya T, Mitchell SG, Rotrosen J, Novo P, et al. Gender ­differences in demographic and clinical characteristics of patients with opioid use disorder entering a comparative effectiveness medication trial. Am J Addict. 2018;27(6):465–70. doi:10.1111/ajad.12784.
   PubMed Web of Science ®Google Scholar
• Evans EA, Zhu Y, Yoo C, Huang D, Hser YI. Criminal justice outcomes over 5 years after randomization to buprenorphine-naloxone or methadone treatment for opioid use disorder. Addiction. 2019;114(8):1396–404. doi:10.1111/add.14620.
   PubMed Web of Science ®Google Scholar
• Krawczyk N, Feder KA, Fingerhood MI, Saloner B. Racial and ethnic differences in opioid agonist treatment for opioid use disorder in a U.S. National Sample. Drug Alcohol Depend. 2017;178:512–8. doi:10.1016/j.drugalcdep.2017.06.009.
   PubMed Web of Science ®Google Scholar
• Abraham AJ, Adams GB, Bradford AC, Bradford WD. County-level access to opioid use disorder medications in medicare Part D (2010-2015). Health Serv Res. 2019;54(2):390–8. doi:10.1111/1475-6773.13113.
   PubMed Web of Science ®Google Scholar
• Abraham AJ, Andrews CM, Harris SJ, Friedmann PD. Availability of medications for the treatment of alcohol and opioid use disorder in the USA. Neurotherapeutics. 2020;17(1):55–69. doi:10.1007/s13311-019-00814-4.
   PubMed Web of Science ®Google Scholar
• Essien UR, Sileanu FE, Zhao X, Liebschutz JM, Thorpe CT, Good CB, Mor MK, Radomski TR, Hausmann LRM, Fine MJ, et al. Racial/ethnic differences in the medical treatment of opioid use disorders within the VA Healthcare System following non-fatal opioid overdose. J Gen Intern Med. 2020;35(5):1537–44. doi:10.1007/s11606-020-05645-0.
   PubMed Web of Science ®Google Scholar
• Guerrero E, Amaro H, Kong Y, Khachikian T, Marsh JC. Gender disparities in opioid treatment progress in methadone versus counseling. Subst Abuse Treat Prev Policy. 2021;16(1):52. doi:10.1186/s13011-021-00389-4.
   PubMed Web of Science ®Google Scholar
• Pro G, Utter J, Haberstroh S, Baldwin JA. Dual mental health diagnoses predict the receipt of medication-assisted opioid treatment: associations moderated by state Medicaid expansion status, race/ethnicity and gender, and year. Drug Alcohol Depend. 2020;209:107952. doi:10.1016/j.drugalcdep.2020.107952.
   PubMed Web of Science ®Google Scholar
• Yang JC, Roman-Urrestarazu A, Brayne C. Responses among substance abuse treatment providers to the opioid epidemic in the USA: variations in buprenorphine and methadone treatment by geography, operational, and payment characteristics, 2007-16. PloS One. 2020;15(3):e0229787. doi:10.1371/journal.pone.0229787.
   PubMed Web of Science ®Google Scholar
• Schiff DM, Nielsen T, Hoeppner BB, Terplan M, Hansen H, Bernson D, Diop H, Bharel M, Krans EE, Selk S, et al. Assessment of racial and ethnic disparities in the use of medication to treat opioid use disorder among pregnant women in Massachusetts. JAMA Netw Open. 2020;3(5):e205734. doi:10.1001/jamanetworkopen.2020.5734.
   PubMed Web of Science ®Google Scholar
• Larochelle MR, Wakeman SE, Ameli O, Chaisson CE, McPheeters JT, Crown WH, Azocar F, Sanghavi DM. Relative cost differences of initial treatment strategies for newly diagnosed opioid use disorder: a cohort study. Med Care. 2020;58(10):919–26. doi:10.1097/MLR.0000000000001394.
   PubMed Web of Science ®Google Scholar
• Yang JC, Roman-Urrestarazu A, Brayne C. Differences in receipt of opioid agonist treatment and time to enter treatment for opioid use disorder among specialty addiction programs in the United States, 2014-17. PloS One. 2019;14(12):e0226349. doi:10.1371/journal.pone.0226349.
   PubMed Web of Science ®Google Scholar
• Abraham AJ, Andrews CM, Yingling ME, Shannon J. Geographic disparities in availability of opioid use disorder treatment for medicaid enrollees. Health Serv Res. 2018;53(1):389–404. doi:10.1111/1475-6773.12686.
   PubMed Web of Science ®Google Scholar
• Amiri S, McDonell MG, Denney JT, Buchwald D, Amram O. Disparities in access to opioid treatment programs and office-based buprenorphine treatment across the rural-urban and area deprivation continua: a us nationwide small area analysis. Value Health: J Int Soc Value Health. 2021;24(2):188–95. doi:10.1016/j.jval.2020.08.2098.
   PubMed Web of Science ®Google Scholar
• Weinstein ZM, Kim HW, Cheng DM, Quinn E, Hui D, Labelle CT, Drainoni M-L, Bachman SS, Samet JH. Long-term retention in office based opioid treatment with buprenorphine. J Subst Abuse Treat. 2017;74:65–70. doi:10.1016/j.jsat.2016.12.010.
   PubMed Web of Science ®Google Scholar
• Mallow PJ, Mercado M, Topmiller M. Disparities in opioid use disorder treatment admissions. JHEOR. 2020;7(1):85–93. doi:10.36469/jheor.2020.13266.
   Google Scholar
• Cantone RE, Garvey B, O'Neill A, Fleishman J, Cohen D, Muench J, Bailey SR. Predictors of medication-assisted treatment initiation for opioid use disorder in an interdisciplinary primary care model. J Am Board Fam 2019;32(5):724–31. doi:10.3122/jabfm.2019.05.190012.
   PubMed Web of Science ®Google Scholar
• Mitchell P, Samsel S, Curtin KM, Price A, Turner D, Tramp R, Hudnall M, Parton J, Lewis D. Geographic disparities in access to medication for opioid use disorder across US census tracts based on treatment utilization behavior. Soc Sci Med. 2022;302:114992. doi:10.1016/j.socscimed.2022.114992.
   PubMed Web of Science ®Google Scholar
• Roy PJ, Choi S, Bernstein E, Walley AY. Appointment wait-times and arrival for patients at a low-barrier access addiction clinic. J Subst Abuse Treat. 2020;114:108011. doi:10.1016/j.jsat.2020.108011.
   PubMed Web of Science ®Google Scholar
• Peles E, Schreiber S, Sason A, Adelson M. Long waiting period to enter methadone maintenance treatment: relation to patient characteristics and outcome. Eur Addict Res. 2012;18(3):149–52. doi:10.1159/000336313.
   PubMed Web of Science ®Google Scholar
• Marsh JC, Amaro H, Kong Y, Khachikian T, Guerrero E. Gender disparities in access and retention in outpatient methadone treatment for opioid use disorder in low-income urban communities. J Subst Abuse Treat. 2021;127:108399. doi:10.1016/j.jsat.2021.108399.
   PubMed Web of Science ®Google Scholar
• Roy PJ, Price R, Choi S, Weinstein ZM, Bernstein E, Cunningham CO, Walley AY. Shorter outpatient wait-times for buprenorphine are associated with linkage to care post-hospital discharge. Drug Alcohol Depend. 2021;224:108703. doi:10.1016/j.drugalcdep.2021.108703.
   PubMed Web of Science ®Google Scholar
• Deyo-Svendsen M, Cabrera Svendsen M, Walker J, Hodges A, Oldfather R, Mansukhani MP. Medication-assisted treatment for opioid use disorder in a rural family medicine practice. J Prim Care Community Health. 2020;11:2150132720931720. doi:10.1177/2150132720931720.
   Web of Science ®Google Scholar
• Loneck B, Garrett J, Banks SM. Engaging and retaining women in outpatient alcohol and other drug treatment: the effect of referral intensity. Health Soc Work. 1997;22(1):38–46. doi:10.1093/hsw/22.1.38.
   PubMed Web of Science ®Google Scholar
• Parran TV, Muller JZ, Chernyak E, Adelman C, Delos Reyes CM, Rowland D, Kolganov M. Access to and payment for office-based buprenorphine treatment in Ohio. Subst Abuse. 2017;11:1178221817699247.
   Web of Science ®Google Scholar
• Lagisetty PA, Ross R, Bohnert A, Clay M, Maust DT. Buprenorphine treatment divide by race/ethnicity and payment. JAMA Psychiatry. 2019;76(9):979–81. doi:10.1001/jamapsychiatry.2019.0876.
   PubMed Web of Science ®Google Scholar
• Mowbray O, Perron BE, Bohnert ASB, Krentzman AR, Vaughn MG. Service use and barriers to care among heroin users: results from a national survey. Am J Drug Alcohol Abuse. 2010;36(6):305–10. doi:10.3109/00952990.2010.503824.
   PubMed Web of Science ®Google Scholar
• Hansen H, Siegel C, Wanderling J, DiRocco D. Buprenorphine and methadone treatment for opioid dependence by income, ethnicity and race of neighborhoods in New York City. Drug Alcohol Depend. 2016;164:14–21. doi:10.1016/j.drugalcdep.2016.03.028.
   PubMed Web of Science ®Google Scholar